Section 50, Intermediate Care Facility for Individuals with Intellectual Disabilities (ICF-IID) Rate Update, CR 113786

Effective January 1, 2023, the Calendar Year (CY) 2023 ICF-IID rate letters will be accessible on the Health PAS Online Portal. You can view them by logging into your Trading Partner Account and following this pathway: File Exchange > Reports > Rate Setting Letters. 

Section 103, Rural Health Clinic (RHC) Rate Update, CR 114016

Effective January 1, 2023, the Calendar Year (CY) 2023 RHC rate letters will be accessible on the Health PAS Online Portal. You can view them by logging into your Trading Partner Account and following this pathway: File Exchange > Reports > Rate Setting Letters. 

If you have questions about accessing the letters, please contact Provider Services at: 1-866-690-5585. If you have questions about the content of the letters, please contact Rate Setting directly using the contact name and phone number on the letters.

Ambulatory Payment Classifications (APC) Claims Overpaying, CR 114133

Some Ambulatory Payment Classifications (APC) claims are overpaying when COVID-19 administration codes are billed in addition to an office visit (i.e., HCPC G0643). The COVID-19 administration code is paying 100% of APC accurately, and the office visit code is paying 100% of APC in error. MaineCare is responsible for paying 100% of APC only on the COVID-19 administration codes. We will notify you once the system is updated. No provider action is needed. Claims that overpaid incorrectly will be adjusted.

 

Reminder for Billing Attending Provider on UB-04 and 837I Claims, CR 110840

This is a reminder that the attending provider is required on all UB-04 and 837I claims.  Effective April 1, 2023, MaineCare will deny UB-04 and 837I claims submitted without an enrolled attending provider.

The attending provider is the individual who has overall responsibility for the patient’s medical care and treatment reported in the claim/encounter. The attending provider requirement includes all claim submission methods (paper, HealthPAS Online Portal, or 837I).

Emergency Use Authorization (EUA) Revoked for Bebtelovimab 175 mg, CR 114106

The Food and Drug Administration (FDA) announced on November 30, 2022, that bebtelovimab, 175mg, no longer has Emergency Use Authorization (EAU).    

 

Eli Lilly EUA Monoclonal Antibody COVID-19 Infusion Treatment-bebtelovimab, 175mg 

 

Electronic Visit Verification (EVV) Trainings and Forums

The federal deadline to implement the EVV requirements for Home Health providers delivering services under Section 40 and Hospice providers delivering services under Section 43 is January 1, 2023.

With these EVV deadlines quickly approaching, we continue to offer weekly provider and aggregator trainings and forums. All trainings and forums are online via Microsoft Teams.

Subscribe to